<DOC>
	<DOCNO>NCT01019265</DOCNO>
	<brief_summary>This trial design comparison evaluation efficacy safety buprenorphine transdermal patch ( Norspan® patch 5 mg , 10 mg 20mg ) oral tramadol ( Tridol® SR ( slow release ) tablet 100mg ) patient moderate severe pain due osteoarthritis .</brief_summary>
	<brief_title>A Study Comparing Norspan Patch Oral Tramadol</brief_title>
	<detailed_description>The primary objective non-inferiority study active , parallel control group compare assess efficacy safety buprenorphine transdermal patch ( Norspan® Patch 5 mg , 10 mg 20 mg ) tramadol ( Tridol® SR ( slow release ) Tablet 100mg ) patient moderate severe pain due osteoarthritis . During period treatment 8weeks , titration maintenance keep 1:1 ratio randomization .</detailed_description>
	<mesh_term>Osteoarthritis</mesh_term>
	<mesh_term>Tramadol</mesh_term>
	<mesh_term>Buprenorphine</mesh_term>
	<criteria>Males female age 18 year . Clinical diagnosis osteoarthritis ( OA ) hip and/or knee include fulfilling American College Rheumatology Criteria ( ACR criterion L13 ) documentation osteoarthritis relevant joint . Patients moderate severe osteoarthritis pain relevant joint , confirm BS11 ( Box Scale11 ) 4 pain average last week , primary OA joint , screen base line visit despite treatment nonopioid analgesic . Patients treat high potency opioid analgesic ( e.g. , morphine , fentanyl , oxycodone , methadone , hydromorphone , ketobemidone , buprenorphine ( include Norspan® ) ) osteoarthritis pain . Patients take opioid analgesic within last 4 week prior screen visit . Patients use ( Nonsteroidal AntiInfammatory ) NSAID transdermal preparation le 2 week prior screen visit .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2015</verification_date>
	<keyword>Norspan patch</keyword>
	<keyword>Buprenorphine transdermal patch ( BTDS )</keyword>
	<keyword>efficacy</keyword>
	<keyword>buprenorphine</keyword>
</DOC>